TO: Members, Advisory Committee for Pharmaceutical Science
FROM: Helen Winkle
Acting Director, Office of Pharmaceutical Science, CDER, FDA
Errata to Memo dated
In the section "Bioavailability / Bioequivalence of Endogenous Drugs", the last sentence should read as follows
"Abbott Laboratories will present an overview of research it conducted on baseline correction methods for leveothyroxine sodium. Some of Abbott's research finding were recently adopted by FDA for bioequivalence testing on levothyroxine products. Abbott will also discuss other approaches for baseline correction."